カテゴリ： 世界, 医療/バイオ, Market Monitor Global

臓器拒絶反応予防薬のグローバル市場展望 2023年-2029年：内服液、注射剤、カプセル

■ 英語タイトル：Drug for Organ Rejection Prophylaxis Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート（データ管理コード：MMG23LY8482）■ 発行会社/調査会社：Market Monitor Global
■ 商品コード：MMG23LY8482
■ 発行日：2023年7月
■ 調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野：医薬品＆ヘルスケア
■ ページ数：126
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[臓器拒絶反応予防薬のグローバル市場展望 2023年-2029年：内服液、注射剤、カプセル]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査レポートは次の情報を含め、世界の臓器拒絶反応予防薬市場規模と予測を収録しています。・世界の臓器拒絶反応予防薬市場：売上、2018年-2023年、2024年-2029年
・世界の臓器拒絶反応予防薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の臓器拒絶反応予防薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「内服液」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

臓器拒絶反応予防薬のグローバル主要企業は、Astellas Pharma US, Inc.、 Pfizer Inc.、 Bausch Health Companies Inc.、 Genentech, Inc.、 Veloxis Pharmaceuticals、 AbbVie、 Bristol Myers Squibb、 Novartis Pharmaceuticals Corp、 Sebela Pharmaceuticals Inc.、 Janssen Biotech, Inc.、 Astellas Pharma US, Inc.、 Adienne Pharma & Biotech、 Sanofi Genzyme Company、 Heumann Pharma GmbH、 Beijing Shuanglu Pharmaceutical Co., Ltd、 North China Pharmaceutical Co., Ltd、 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd、 Tianjin Central Pharmaceutical Co., Ltd、 Nantong Jingjing Pharmaceutical Co., Ltd、 Shanghai Pharmaceutical Groupなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、臓器拒絶反応予防薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の臓器拒絶反応予防薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の臓器拒絶反応予防薬市場：タイプ別市場シェア、2022年
・内服液、注射剤、カプセル

世界の臓器拒絶反応予防薬市場：用途別、2018年-2023年、2024年-2029年
世界の臓器拒絶反応予防薬市場：用途別市場シェア、2022年
・病院、専門医院、その他

世界の臓器拒絶反応予防薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の臓器拒絶反応予防薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における臓器拒絶反応予防薬のグローバル売上、2018年-2023年
・主要企業における臓器拒絶反応予防薬のグローバル売上シェア、2022年
・主要企業における臓器拒絶反応予防薬のグローバル販売量、2018年-2023年
・主要企業における臓器拒絶反応予防薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Astellas Pharma US, Inc.、 Pfizer Inc.、 Bausch Health Companies Inc.、 Genentech, Inc.、 Veloxis Pharmaceuticals、 AbbVie、 Bristol Myers Squibb、 Novartis Pharmaceuticals Corp、 Sebela Pharmaceuticals Inc.、 Janssen Biotech, Inc.、 Astellas Pharma US, Inc.、 Adienne Pharma & Biotech、 Sanofi Genzyme Company、 Heumann Pharma GmbH、 Beijing Shuanglu Pharmaceutical Co., Ltd、 North China Pharmaceutical Co., Ltd、 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd、 Tianjin Central Pharmaceutical Co., Ltd、 Nantong Jingjing Pharmaceutical Co., Ltd、 Shanghai Pharmaceutical Group

*************************************************************

・調査・分析レポートの概要
臓器拒絶反応予防薬市場の定義
市場セグメント
世界の臓器拒絶反応予防薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の臓器拒絶反応予防薬市場規模
世界の臓器拒絶反応予防薬市場規模：2022年 VS 2029年
世界の臓器拒絶反応予防薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの臓器拒絶反応予防薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の臓器拒絶反応予防薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：内服液、注射剤、カプセル
臓器拒絶反応予防薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、専門医院、その他
臓器拒絶反応予防薬の用途別グローバル売上・予測

・地域別市場分析
地域別臓器拒絶反応予防薬市場規模 2022年と2029年
地域別臓器拒絶反応予防薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Astellas Pharma US, Inc.、 Pfizer Inc.、 Bausch Health Companies Inc.、 Genentech, Inc.、 Veloxis Pharmaceuticals、 AbbVie、 Bristol Myers Squibb、 Novartis Pharmaceuticals Corp、 Sebela Pharmaceuticals Inc.、 Janssen Biotech, Inc.、 Astellas Pharma US, Inc.、 Adienne Pharma & Biotech、 Sanofi Genzyme Company、 Heumann Pharma GmbH、 Beijing Shuanglu Pharmaceutical Co., Ltd、 North China Pharmaceutical Co., Ltd、 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd、 Tianjin Central Pharmaceutical Co., Ltd、 Nantong Jingjing Pharmaceutical Co., Ltd、 Shanghai Pharmaceutical Group
...

Organ rejection preventive drugs are used to prevent the immune system from attacking, destroying and clearing “alien ingredients” such as bacteria, viruses, foreign bodies, foreign tissues and artificial materials
This report aims to provide a comprehensive presentation of the global market for Drug for Organ Rejection Prophylaxis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drug for Organ Rejection Prophylaxis. This report contains market size and forecasts of Drug for Organ Rejection Prophylaxis in global, including the following market information:
Global Drug for Organ Rejection Prophylaxis Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Drug for Organ Rejection Prophylaxis Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Drug for Organ Rejection Prophylaxis companies in 2022 (%)
The global Drug for Organ Rejection Prophylaxis market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Oral Liquid Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Drug for Organ Rejection Prophylaxis include Astellas Pharma US, Inc., Pfizer Inc., Bausch Health Companies Inc., Genentech, Inc., Veloxis Pharmaceuticals, AbbVie, Bristol Myers Squibb, Novartis Pharmaceuticals Corp and Sebela Pharmaceuticals Inc., etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Drug for Organ Rejection Prophylaxis manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Drug for Organ Rejection Prophylaxis Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Drug for Organ Rejection Prophylaxis Market Segment Percentages, by Type, 2022 (%)
Oral Liquid
Injection
Capsule
Global Drug for Organ Rejection Prophylaxis Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Drug for Organ Rejection Prophylaxis Market Segment Percentages, by Application, 2022 (%)
Hospital
Specialist Clinic
Other
Global Drug for Organ Rejection Prophylaxis Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Drug for Organ Rejection Prophylaxis Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Drug for Organ Rejection Prophylaxis revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Drug for Organ Rejection Prophylaxis revenues share in global market, 2022 (%)
Key companies Drug for Organ Rejection Prophylaxis sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Drug for Organ Rejection Prophylaxis sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Astellas Pharma US, Inc.
Pfizer Inc.
Bausch Health Companies Inc.
Genentech, Inc.
Veloxis Pharmaceuticals
AbbVie
Bristol Myers Squibb
Novartis Pharmaceuticals Corp
Sebela Pharmaceuticals Inc.
Janssen Biotech, Inc.
Astellas Pharma US, Inc.
Adienne Pharma & Biotech
Sanofi Genzyme Company
Heumann Pharma GmbH
Beijing Shuanglu Pharmaceutical Co., Ltd
North China Pharmaceutical Co., Ltd
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd
Tianjin Central Pharmaceutical Co., Ltd
Nantong Jingjing Pharmaceutical Co., Ltd
Shanghai Pharmaceutical Group
Outline of Major Chapters:
Chapter 1: Introduces the definition of Drug for Organ Rejection Prophylaxis, market overview.
Chapter 2: Global Drug for Organ Rejection Prophylaxis market size in revenue and volume.
Chapter 3: Detailed analysis of Drug for Organ Rejection Prophylaxis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Drug for Organ Rejection Prophylaxis in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Drug for Organ Rejection Prophylaxis capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Introduction to Research & Analysis Reports
1.1 Drug for Organ Rejection Prophylaxis Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Drug for Organ Rejection Prophylaxis Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Drug for Organ Rejection Prophylaxis Overall Market Size
2.1 Global Drug for Organ Rejection Prophylaxis Market Size: 2022 VS 2029
2.2 Global Drug for Organ Rejection Prophylaxis Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Drug for Organ Rejection Prophylaxis Sales: 2018-2029
3 Company Landscape
3.1 Top Drug for Organ Rejection Prophylaxis Players in Global Market
3.2 Top Global Drug for Organ Rejection Prophylaxis Companies Ranked by Revenue
3.3 Global Drug for Organ Rejection Prophylaxis Revenue by Companies
3.4 Global Drug for Organ Rejection Prophylaxis Sales by Companies
3.5 Global Drug for Organ Rejection Prophylaxis Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Drug for Organ Rejection Prophylaxis Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Drug for Organ Rejection Prophylaxis Product Type
3.8 Tier 1, Tier 2 and Tier 3 Drug for Organ Rejection Prophylaxis Players in Global Market
3.8.1 List of Global Tier 1 Drug for Organ Rejection Prophylaxis Companies
3.8.2 List of Global Tier 2 and Tier 3 Drug for Organ Rejection Prophylaxis Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Drug for Organ Rejection Prophylaxis Market Size Markets, 2022 & 2029
4.1.2 Oral Liquid
4.1.3 Injection
4.1.4 Capsule
4.2 By Type – Global Drug for Organ Rejection Prophylaxis Revenue & Forecasts
4.2.1 By Type – Global Drug for Organ Rejection Prophylaxis Revenue, 2018-2023
4.2.2 By Type – Global Drug for Organ Rejection Prophylaxis Revenue, 2024-2029
4.2.3 By Type – Global Drug for Organ Rejection Prophylaxis Revenue Market Share, 2018-2029
4.3 By Type – Global Drug for Organ Rejection Prophylaxis Sales & Forecasts
4.3.1 By Type – Global Drug for Organ Rejection Prophylaxis Sales, 2018-2023
4.3.2 By Type – Global Drug for Organ Rejection Prophylaxis Sales, 2024-2029
4.3.3 By Type – Global Drug for Organ Rejection Prophylaxis Sales Market Share, 2018-2029
4.4 By Type – Global Drug for Organ Rejection Prophylaxis Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Drug for Organ Rejection Prophylaxis Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Specialist Clinic
5.1.4 Other
5.2 By Application – Global Drug for Organ Rejection Prophylaxis Revenue & Forecasts
5.2.1 By Application – Global Drug for Organ Rejection Prophylaxis Revenue, 2018-2023
5.2.2 By Application – Global Drug for Organ Rejection Prophylaxis Revenue, 2024-2029
5.2.3 By Application – Global Drug for Organ Rejection Prophylaxis Revenue Market Share, 2018-2029
5.3 By Application – Global Drug for Organ Rejection Prophylaxis Sales & Forecasts
5.3.1 By Application – Global Drug for Organ Rejection Prophylaxis Sales, 2018-2023
5.3.2 By Application – Global Drug for Organ Rejection Prophylaxis Sales, 2024-2029
5.3.3 By Application – Global Drug for Organ Rejection Prophylaxis Sales Market Share, 2018-2029
5.4 By Application – Global Drug for Organ Rejection Prophylaxis Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Drug for Organ Rejection Prophylaxis Market Size, 2022 & 2029
6.2 By Region – Global Drug for Organ Rejection Prophylaxis Revenue & Forecasts
6.2.1 By Region – Global Drug for Organ Rejection Prophylaxis Revenue, 2018-2023
6.2.2 By Region – Global Drug for Organ Rejection Prophylaxis Revenue, 2024-2029
6.2.3 By Region – Global Drug for Organ Rejection Prophylaxis Revenue Market Share, 2018-2029
6.3 By Region – Global Drug for Organ Rejection Prophylaxis Sales & Forecasts
6.3.1 By Region – Global Drug for Organ Rejection Prophylaxis Sales, 2018-2023
6.3.2 By Region – Global Drug for Organ Rejection Prophylaxis Sales, 2024-2029
6.3.3 By Region – Global Drug for Organ Rejection Prophylaxis Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Drug for Organ Rejection Prophylaxis Revenue, 2018-2029
6.4.2 By Country – North America Drug for Organ Rejection Prophylaxis Sales, 2018-2029
6.4.3 US Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.4.4 Canada Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.4.5 Mexico Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Drug for Organ Rejection Prophylaxis Revenue, 2018-2029
6.5.2 By Country – Europe Drug for Organ Rejection Prophylaxis Sales, 2018-2029
6.5.3 Germany Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.5.4 France Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.5.5 U.K. Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.5.6 Italy Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.5.7 Russia Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.5.8 Nordic Countries Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.5.9 Benelux Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Drug for Organ Rejection Prophylaxis Revenue, 2018-2029
6.6.2 By Region – Asia Drug for Organ Rejection Prophylaxis Sales, 2018-2029
6.6.3 China Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.6.4 Japan Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.6.5 South Korea Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.6.6 Southeast Asia Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.6.7 India Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Drug for Organ Rejection Prophylaxis Revenue, 2018-2029
6.7.2 By Country – South America Drug for Organ Rejection Prophylaxis Sales, 2018-2029
6.7.3 Brazil Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.7.4 Argentina Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Drug for Organ Rejection Prophylaxis Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Drug for Organ Rejection Prophylaxis Sales, 2018-2029
6.8.3 Turkey Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.8.4 Israel Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.8.5 Saudi Arabia Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
6.8.6 UAE Drug for Organ Rejection Prophylaxis Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Astellas Pharma US, Inc.
7.1.1 Astellas Pharma US, Inc. Company Summary
7.1.2 Astellas Pharma US, Inc. Business Overview
7.1.3 Astellas Pharma US, Inc. Drug for Organ Rejection Prophylaxis Major Product Offerings
7.1.4 Astellas Pharma US, Inc. Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.1.5 Astellas Pharma US, Inc. Key News & Latest Developments
7.2 Pfizer Inc.
7.2.1 Pfizer Inc. Company Summary
7.2.2 Pfizer Inc. Business Overview
7.2.3 Pfizer Inc. Drug for Organ Rejection Prophylaxis Major Product Offerings
7.2.4 Pfizer Inc. Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.2.5 Pfizer Inc. Key News & Latest Developments
7.3 Bausch Health Companies Inc.
7.3.1 Bausch Health Companies Inc. Company Summary
7.3.2 Bausch Health Companies Inc. Business Overview
7.3.3 Bausch Health Companies Inc. Drug for Organ Rejection Prophylaxis Major Product Offerings
7.3.4 Bausch Health Companies Inc. Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.3.5 Bausch Health Companies Inc. Key News & Latest Developments
7.4 Genentech, Inc.
7.4.1 Genentech, Inc. Company Summary
7.4.2 Genentech, Inc. Business Overview
7.4.3 Genentech, Inc. Drug for Organ Rejection Prophylaxis Major Product Offerings
7.4.4 Genentech, Inc. Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.4.5 Genentech, Inc. Key News & Latest Developments
7.5 Veloxis Pharmaceuticals
7.5.1 Veloxis Pharmaceuticals Company Summary
7.5.2 Veloxis Pharmaceuticals Business Overview
7.5.3 Veloxis Pharmaceuticals Drug for Organ Rejection Prophylaxis Major Product Offerings
7.5.4 Veloxis Pharmaceuticals Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.5.5 Veloxis Pharmaceuticals Key News & Latest Developments
7.6 AbbVie
7.6.1 AbbVie Company Summary
7.6.2 AbbVie Business Overview
7.6.3 AbbVie Drug for Organ Rejection Prophylaxis Major Product Offerings
7.6.4 AbbVie Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.6.5 AbbVie Key News & Latest Developments
7.7 Bristol Myers Squibb
7.7.1 Bristol Myers Squibb Company Summary
7.7.2 Bristol Myers Squibb Business Overview
7.7.3 Bristol Myers Squibb Drug for Organ Rejection Prophylaxis Major Product Offerings
7.7.4 Bristol Myers Squibb Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.7.5 Bristol Myers Squibb Key News & Latest Developments
7.8 Novartis Pharmaceuticals Corp
7.8.1 Novartis Pharmaceuticals Corp Company Summary
7.8.2 Novartis Pharmaceuticals Corp Business Overview
7.8.3 Novartis Pharmaceuticals Corp Drug for Organ Rejection Prophylaxis Major Product Offerings
7.8.4 Novartis Pharmaceuticals Corp Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.8.5 Novartis Pharmaceuticals Corp Key News & Latest Developments
7.9 Sebela Pharmaceuticals Inc.
7.9.1 Sebela Pharmaceuticals Inc. Company Summary
7.9.2 Sebela Pharmaceuticals Inc. Business Overview
7.9.3 Sebela Pharmaceuticals Inc. Drug for Organ Rejection Prophylaxis Major Product Offerings
7.9.4 Sebela Pharmaceuticals Inc. Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.9.5 Sebela Pharmaceuticals Inc. Key News & Latest Developments
7.10 Janssen Biotech, Inc.
7.10.1 Janssen Biotech, Inc. Company Summary
7.10.2 Janssen Biotech, Inc. Business Overview
7.10.3 Janssen Biotech, Inc. Drug for Organ Rejection Prophylaxis Major Product Offerings
7.10.4 Janssen Biotech, Inc. Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.10.5 Janssen Biotech, Inc. Key News & Latest Developments
7.11 Astellas Pharma US, Inc.
7.11.1 Astellas Pharma US, Inc. Company Summary
7.11.2 Astellas Pharma US, Inc. Drug for Organ Rejection Prophylaxis Business Overview
7.11.3 Astellas Pharma US, Inc. Drug for Organ Rejection Prophylaxis Major Product Offerings
7.11.4 Astellas Pharma US, Inc. Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.11.5 Astellas Pharma US, Inc. Key News & Latest Developments
7.12 Adienne Pharma & Biotech
7.12.1 Adienne Pharma & Biotech Company Summary
7.12.2 Adienne Pharma & Biotech Drug for Organ Rejection Prophylaxis Business Overview
7.12.3 Adienne Pharma & Biotech Drug for Organ Rejection Prophylaxis Major Product Offerings
7.12.4 Adienne Pharma & Biotech Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.12.5 Adienne Pharma & Biotech Key News & Latest Developments
7.13 Sanofi Genzyme Company
7.13.1 Sanofi Genzyme Company Company Summary
7.13.2 Sanofi Genzyme Company Drug for Organ Rejection Prophylaxis Business Overview
7.13.3 Sanofi Genzyme Company Drug for Organ Rejection Prophylaxis Major Product Offerings
7.13.4 Sanofi Genzyme Company Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.13.5 Sanofi Genzyme Company Key News & Latest Developments
7.14 Heumann Pharma GmbH
7.14.1 Heumann Pharma GmbH Company Summary
7.14.2 Heumann Pharma GmbH Business Overview
7.14.3 Heumann Pharma GmbH Drug for Organ Rejection Prophylaxis Major Product Offerings
7.14.4 Heumann Pharma GmbH Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.14.5 Heumann Pharma GmbH Key News & Latest Developments
7.15 Beijing Shuanglu Pharmaceutical Co., Ltd
7.15.1 Beijing Shuanglu Pharmaceutical Co., Ltd Company Summary
7.15.2 Beijing Shuanglu Pharmaceutical Co., Ltd Business Overview
7.15.3 Beijing Shuanglu Pharmaceutical Co., Ltd Drug for Organ Rejection Prophylaxis Major Product Offerings
7.15.4 Beijing Shuanglu Pharmaceutical Co., Ltd Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.15.5 Beijing Shuanglu Pharmaceutical Co., Ltd Key News & Latest Developments
7.16 North China Pharmaceutical Co., Ltd
7.16.1 North China Pharmaceutical Co., Ltd Company Summary
7.16.2 North China Pharmaceutical Co., Ltd Business Overview
7.16.3 North China Pharmaceutical Co., Ltd Drug for Organ Rejection Prophylaxis Major Product Offerings
7.16.4 North China Pharmaceutical Co., Ltd Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.16.5 North China Pharmaceutical Co., Ltd Key News & Latest Developments
7.17 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd
7.17.1 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd Company Summary
7.17.2 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd Business Overview
7.17.3 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd Drug for Organ Rejection Prophylaxis Major Product Offerings
7.17.4 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.17.5 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd Key News & Latest Developments
7.18 Tianjin Central Pharmaceutical Co., Ltd
7.18.1 Tianjin Central Pharmaceutical Co., Ltd Company Summary
7.18.2 Tianjin Central Pharmaceutical Co., Ltd Business Overview
7.18.3 Tianjin Central Pharmaceutical Co., Ltd Drug for Organ Rejection Prophylaxis Major Product Offerings
7.18.4 Tianjin Central Pharmaceutical Co., Ltd Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.18.5 Tianjin Central Pharmaceutical Co., Ltd Key News & Latest Developments
7.19 Nantong Jingjing Pharmaceutical Co., Ltd
7.19.1 Nantong Jingjing Pharmaceutical Co., Ltd Company Summary
7.19.2 Nantong Jingjing Pharmaceutical Co., Ltd Business Overview
7.19.3 Nantong Jingjing Pharmaceutical Co., Ltd Drug for Organ Rejection Prophylaxis Major Product Offerings
7.19.4 Nantong Jingjing Pharmaceutical Co., Ltd Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.19.5 Nantong Jingjing Pharmaceutical Co., Ltd Key News & Latest Developments
7.20 Shanghai Pharmaceutical Group
7.20.1 Shanghai Pharmaceutical Group Company Summary
7.20.2 Shanghai Pharmaceutical Group Business Overview
7.20.3 Shanghai Pharmaceutical Group Drug for Organ Rejection Prophylaxis Major Product Offerings
7.20.4 Shanghai Pharmaceutical Group Drug for Organ Rejection Prophylaxis Sales and Revenue in Global (2018-2023)
7.20.5 Shanghai Pharmaceutical Group Key News & Latest Developments
8 Global Drug for Organ Rejection Prophylaxis Production Capacity, Analysis
8.1 Global Drug for Organ Rejection Prophylaxis Production Capacity, 2018-2029
8.2 Drug for Organ Rejection Prophylaxis Production Capacity of Key Manufacturers in Global Market
8.3 Global Drug for Organ Rejection Prophylaxis Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Drug for Organ Rejection Prophylaxis Supply Chain Analysis
10.1 Drug for Organ Rejection Prophylaxis Industry Value Chain
10.2 Drug for Organ Rejection Prophylaxis Upstream Market
10.3 Drug for Organ Rejection Prophylaxis Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Drug for Organ Rejection Prophylaxis Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • アカルボース医薬品のグローバル市場展望 2023年-2029年：錠剤、カプセル
  • 植物由来医薬品のグローバル市場展望 2023年-2029年：丸薬、錠剤、カプセル
  • リファマイシンのグローバル市場展望 2023年-2029年：タブレット、カプセル
  • 医療用ビスマスのグローバル市場展望 2023年-2029年：懸濁液、カプセル、微粒子
  • 肝胆道疾患向けウルソデオキシコール酸製剤のグローバル市場展望 2023年-2029年：カプセル、錠剤
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(MMG23LY8482 )"臓器拒絶反応予防薬のグローバル市場展望 2023年-2029年：内服液、注射剤、カプセル" (英文：Drug for Organ Rejection Prophylaxis Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。